A retrospective study of memantine in children and adolescents with pervasive developmental disorders

@article{Erickson2006ARS,
  title={A retrospective study of memantine in children and adolescents with pervasive developmental disorders},
  author={Craig A. Erickson and David J. Posey and Kimberly A. Stigler and Jennifer E. Mullett and Adrian Katschke and Christopher J. McDougle},
  journal={Psychopharmacology},
  year={2006},
  volume={191},
  pages={141-147}
}
RationaleThere are no drugs that have been shown to effectively treat the core social impairment of autism.ObjectivesThe purpose of this study was to examine the effectiveness and tolerability of memantine for social impairment in children and adolescents with pervasive developmental disorders (PDDs).Materials and methodsMedical records of 18 patients with PDDs consecutively treated with open-label memantine were retrospectively reviewed. The data reviewed included prospectively obtained… Expand

Paper Mentions

Interventional Clinical Trial
The purpose of this research study is to learn if the medication Memantine Hydrochloride (the study medication) can help adolescents and young adults with Down syndrome. Dr. Alberto… Expand
ConditionsDown Syndrome, Intellectual Disability
InterventionDrug
Efficacy of Memantine as Adjunct Therapy for Autism Spectrum Disorder in Children Aged <14 Years
TLDR
Memantine administration as adjunct therapy can be more effective in improvement of ASD symptoms in children than ABA alone and can be considered as a new selective adjunct therapy. Expand
A Prospective Open-Label Trial of Memantine Hydrochloride for the Treatment of Social Deficits in Intellectually Capable Adults With Autism Spectrum Disorder
TLDR
Treatment with memantine appears to be beneficial for the treatment of ASD and associated psychopathology and cognitive dysfunction in intellectually capable adults. Expand
Memantine: a review of possible uses in child and adolescent psychiatry.
  • Sheik Hosenbocus, Raj Chahal
  • Medicine
  • Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent
  • 2013
TLDR
Memantine has demonstrated beneficial effects in some childhood disorders but the evidence is too limited at present and does not provide enough support of its efficacy to advocate for its regular use in those conditions, so use remains off-label until further validation of efficacy comes from blinded, randomized, placebo controlled studies. Expand
An open-label naturalistic pilot study of acamprosate in youth with autistic disorder.
TLDR
This study describes the initial open-label experience with acamprosate targeting social impairment in youth with autism and reports that the drug was well tolerated with only mild gastrointestinal adverse effects noted in three subjects. Expand
A retrospective analysis of memantine use in a pediatric neurology clinic
TLDR
Memantine is generally well-tolerated in children, and may have potential benefit for a broad range of pediatric neurodevelopmental disorders. Expand
Safety and Efficacy of Memantine in Children with Autism: Randomized, Placebo-Controlled Study and Open-Label Extension
TLDR
This trial did not demonstrate clinical efficacy of memantine ER in autism; however, the tolerability and safety data were reassuring and could inform future trial design in this population and may facilitate the investigation of Memantine ER for other clinical applications. Expand
Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial.
TLDR
The present study suggests that memantine may be a potential adjunctive treatment strategy for autism and it was generally well tolerated. Expand
Minocycline as Adjunctive Treatment to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial.
TLDR
Minocycline seems to be a safe and effective adjuvant in management of patients with autistic disorder and inflammatory cytokine measurements are warranted to confirm these findings. Expand
Use of Memantine in Autism Spectrum Disorder: a Case Report
TLDR
Memantine appeared effective for treating core deficits in verbal and non-verbal communication in a child with autism, and improvement in communication was noted over the course of one year of treatment with memantine. Expand
l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.
TLDR
Although no significant difference was detected on the irritability subscale scores, l-carnosine add-on can improve hyperactivity/noncompliance subscales of the ABC-C rating scale in patients with ASD. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 31 REFERENCES
A pilot study of D-cycloserine in subjects with autistic disorder.
TLDR
D-cycloserine treatment resulted in significant improvement in social withdrawal in subjects with autism, and d-Cycloserine was well tolerated at most of the doses used in this study. Expand
Pervasive developmental disorders in preschool children.
TLDR
The authors' results suggest that rates of PDD are higher than previously reported, and attention is nevertheless drawn to the important needs of a substantial minority of preschool children. Expand
Pervasive developmental disorders in preschool children: confirmation of high prevalence.
TLDR
The rate of reported pervasive developmental disorders has increased, and the authors found a rate of 62.6 per 10,000 in a previous study of preschoolers in Stafford, U.K, suggesting a stable incidence. Expand
CURRENT AND EMERGING THERAPEUTICS OF AUTISTIC DISORDER AND RELATED PERVASIVE DEVELOPMENTAL DISORDERS
Pervasive developmental disorders (PDDs) are characterized by severe and pervasive impairment in several areas of development, including reciprocal social interaction skills, communication skills,Expand
A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
TLDR
The hypothesis that agents acting at the glycine modulatory site of the NMDA receptor improve primary negative symptoms is supported, which was predicted by low neuroleptic dose and low baseline SANS total score. Expand
The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.
TLDR
The development of a scale to assess drug and other treatment effects on severely mentally retarded individuals was described and the results were compared with empirically derived rating scales of childhood psychopathology and with factor analytic work in the field of mental retardation. Expand
Neurochemical alterations in Rett syndrome.
TLDR
The results suggest that changes in specific neurotransmitter systems, particularly cholinergic neurons, in the thalamus, cerebellum and basal ganglia may underlie the progressive deterioration in motor and cognitive function characteristic of this disorder. Expand
Hypothesis: Is infantile autism a hypoglutamatergic disorder? Relevance of glutamate – serotonin interactions for pharmacotherapy
  • M. Carlsson
  • Psychology, Medicine
  • Journal of Neural Transmission
  • 1998
TLDR
It is proposed in the present paper that infantile autism is a hypoglutamatergic disorder and possible future pharmacological interventions in autism are discussed in the light of the intimate interplay between central glutamate and serotonin. Expand
Memantine in Moderate-to-severe Alzheimer's Disease
Alzheimer’s disease (AD) is the most common cause of dementia. It is a progressive neurodegenerative disorder resulting in cognitive and behavioural impairment of sufficient severity to markedlyExpand
Development of amino acid receptors in frontal cortex from girls with Rett syndrome
TLDR
The results showed a trend for the densities of NMDA, AMPA, gamma‐aminobutyric acid, and metabotropic glutamate receptors to be higher in younger patients than in controls and for densities in older patients to fall below those of controls. Expand
...
1
2
3
4
...